Hot Regional Bank Stocks To Invest In Right Now

Hot Regional Bank Stocks To Invest In Right Now: Bayer AG (BAYRY.PK)

Bayer AG is a management holding company. The Companys business operations are organized into three subgroups: HealthCare, CropScience and MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare is involved in the research, development and manufacture of health products for people and animals. Bayer CropScience is engaged in the crop protection and non-agricultural pest control. Bayer MaterialScience supplies polymers, and develops solution for a range of applications. In November 2009, Bayer MaterialScience acquired the polymer coatings business from Lombard Medical Technologies PLC. On November 2, 2009, it acquired Athenix Corporation. On October 1, 2009, it acquired two dermatology product lines from SkinMedica, Inc., Carlsbad, California, United States. On June 25, 2009, it acquired the remaining 10% interest in Bayer Polymers (Shanghai) Co. Ltd., China. In May 2009, it acquired the remain ing 49% interest in Berlimed, s.a., Spain, from Juste s.a. Quimica Farmac茅utica (Juste), and in return sold its 51% interest of Justesa Imagen, s.a., Spain, to Juste. In May 2009, it also sold the Thermoplastics Testing Center, Krefeld, Germany, to Underwriters Laboratories Inc. In March 2010, the Company announced that its Bayer MaterialScience LLC has acquired Artificial Muscle, Inc, a company active in electroactive polymers for the consumer electronics industry.

Bayer HealthCare

The Company researches, develops, manufactures pharmaceutical and medical products. Bayer HealthCare operates in four operating divisions: Animal Health, which is engaged in manufacture of veterinary medicines and grooming products; Bayer Schering Pharma, which is engaged in manufacture of prescription medicines; Consumer Care, which is engaged in the manufacture of over-the-counter medicines and dietary supplements, and Medical Care, which is engage! d in manufacture of blood glucose monitoring devices and contrast agent injection systems. Its products for farm animals include Baytril. Its products for companion animals include Advantage/Advantix and Baytril. Its drug discovery in the pharmaceuticals segment focuses on the areas of cardiology, oncology,

womens healthcare and diagnostic imaging.

Bayer CropScience

CropScience maintains a global network of research and development facilities. In the Crop Protection segment it identifies and develops safe and economically sustainable insecticides, fungicides and herbicides and carries its research projects in areas, such as plant health or stress tolerance. As of December 31, 2009, its active ingredient pipeline of Crop Protection contained 20 development projects, of which 10 was at an advanced stage and 10 at an early stage of development, and an additional 45 projects was undergoing early-stage research. Its operations are structured into six business ope rations units: four regional Crop Protection units plus the Environmental Science and BioScience units. Its insecticides include Confidor/ Admire, Calypso, Decis, Temik and Oberon. Its fungicides include Antracol, Fandango, Flint/Stratego/Sphere/Twist, Folicur and Previcur Energy. Its herbicides include Atlantis, Basta, Betanal, Fenikan, Hoestar, Husar, MaisTer, Puma. Its seed treatment products include Bariton, Gaucho, Lamarador, Poncho and Raxil.

Bayer MaterialScience

The Company supplies materials, such as polycarbonates and polyurethanes and system solutions for a range of everyday uses. It operates in three business units: Polyurethanes, Polycarbonates, and Coatings, Adhesives and Specialties. Its Coatings, Adhesives, Specialties producst include Desmodur, Bayhydur, Dispercoll and Artwalk. Its Polycarbonates include Makrolon, Makrofol / Bayfol, Fantasia and Bayblend. Its Polyurethanes include Multitec, Baydur, Bayflex, Baypreg and Vulkollan. I ts Thermoplastic Polyurethanes include! Desmopan! / Texin.

Advisors' Opinion:

• [By Henry Kawabe]

  In June, Seattle Genetics announced it entered into a collaboration with Bayer HealthCare (BAYRY.PK) for access to its Seattle Genetics' auristatin-based ADC technology to create cancer drugs that home in on tumors and then deliver a toxic dose to their cells. The collaboration will generate upfront and option exercise fees of up to $20 million. Seattle Genetics is also eligible to receive up to approximately $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/hot-regional-bank-stocks-to-invest-in-right-now-3.html